Comparative Pharmacology
Head-to-head clinical analysis: SUMAVEL DOSEPRO versus ZOMIG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SUMAVEL DOSEPRO versus ZOMIG.
SUMAVEL DOSEPRO vs ZOMIG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sumatriptan is a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist, causing vasoconstriction of intracranial blood vessels and inhibition of trigeminal nerve transmission.
Selective 5-HT1B/1D receptor agonist; constricts cranial blood vessels and inhibits trigeminal nerve transmission.
Sumavel DosePro (sumatriptan injection) is administered subcutaneously via a single-use needle-free injector. The typical adult dose is 6 mg subcutaneously once, with a maximum of 6 mg per 24 hours. A second injection may be given at least 1 hour after the first if symptoms recur, but not more than two injections in 24 hours.
2.5 mg orally at onset of migraine; may repeat after 2 hours if needed, maximum 10 mg in 24 hours. Also available as 5 mg nasal spray and 3 mg subcutaneous injection.
None Documented
None Documented
Terminal elimination half-life is 2.5–3 hours. Clinical context: Short half-life allows titrated dosing; may prolong in hepatic impairment.
Mean terminal elimination half-life is approximately 3 hours (range 2.5-4 hours). In patients with hepatic impairment, half-life may be prolonged (up to 7 hours).
Primarily renal (60% unchanged, 20% as indole acetic acid metabolite) and fecal (about 10%). Biliary excretion contributes minimally.
Primarily hepatic metabolism via CYP1A2; approximately 10-15% excreted unchanged in urine, with the remainder eliminated as metabolites (mostly N-desmethylzolmitriptan and indoleacetic acid) in urine (60%) and feces (30%).
Category C
Category C
Triptan Antimigraine
Triptan Antimigraine